EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis

Yu Fujiwara iD, Yui Okamura, Mrinalini Ramesh, Yasmin Fakhari Tehrani, Riona Aburaki iD, Toshiaki Takahashi iD, Manmeet S Ahluwalia, Sarbajit Mukherjee iD

JNCI Cancer Spectrum · 07.07.2026 · 10 (4)

DOI: 10.1093/jncics/pkag066 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 18.06.2026. Verfasst von Yu Fujiwara und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States. Hauptthemen laut MEDLINE: Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Novel agents targeting immune checkpoints are under development to overcome resistance to PD-1/PD-L1 and CTLA-4 blockade. Incidences of immune-related adverse events (irAEs) and toxicity profiles of novel agents remain unelucidated.

Methods

We searched PubMed/MEDLINE, Embase, and Web of Science for clinical trials evaluating agents targeting co-inhibitory (B7-H3, CD47, TIGIT, LAG-3, and TIM-3) or co-stimulatory checkpoints (OX40, 4-1BB, CD27, ICOS, GITR, CD70, and CD40) in solid tumors. Incidences of any-grade and grade 3-5 (G3-5) treatment-related AEs (trAEs) and irAEs were extracted from phase 2 and 3 trials, and phase 1/2 trials with safety information reported at the recommended phase 2 dose. Odds ratios (ORs) from 2-arm studies evaluating the addition of LAG-3 or TIGIT blockade to control-arm therapy were pooled, and AE incidences across immunotherapy subtypes were reported using a random-effects meta-analysis.

Results

A systematic review identified 27 clinical trials comprising 3946 patients. The addition of LAG-3 blockade increased G3-5 trAEs (OR = 1.79, 95% confidence interval [CI] = 1.26 to 2.54, P = .001), adrenal insufficiency (G3-5: OR = 8.43, 95% CI = 1.04 to 68.37, P = .046; any-grade: OR = 4.81, 95% CI = 1.81 to 12.78, P = .002) and any-grade arthralgia (OR = 2.07, 95% CI = 1.29 to 3.30, P = .002). Adding TIGIT blockade increased any-grade rash (OR = 2.32, 95% CI = 1.01 to 5.34, P = .048). Meta-analyses revealed varying irAE patterns: G5 trAEs (0.9%-2.9%), G3-5 pneumonitis (0.5%-5.5%, highest in TIM-3), G3-5 colitis (0.2%-5.4%, highest in LAG-3), G3-5 hepatitis (1.5%-5.5%, highest in TIM-3), and G3-5 adrenal insufficiency (1.7%-8.4%, highest in TIGIT).

Conclusions

This study highlights the distinct toxicity profiles of novel immunotherapy agents, providing essential safety data to support clinicians as these therapies approach approval.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmune Checkpoint InhibitorsHumansCTLA-4 AntigenProgrammed Cell Death 1 ReceptorB7-H1 AntigenAntigens, CDLymphocyte Activation Gene 3 ProteinReceptors, ImmunologicImmunotherapy

Substanzen

Immune Checkpoint InhibitorsCTLA-4 AntigenProgrammed Cell Death 1 ReceptorB7-H1 AntigenAntigens, CDCD274 protein, humanLymphocyte Activation Gene 3 ProteinCTLA4 protein, humanPDCD1 protein, humanLag3 protein, human

Autor:innen und Institutionen

  • Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Department of Clinical Oncology, Institute of Science Tokyo, Tokyo, Japan.
  • Department of Medicine, University at Buffalo, Buffalo, NY, United States.
  • College of Medicine, School of Medicine and Health Sciences, University of Tsukuba, Tsukuba, Japan.
  • Yokohama City University, Yokohama City University School of Medicine, Yokohama, Japan.
  • Department of Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI, United States.

ORCID-Profile: Yu Fujiwara, Riona Aburaki, Toshiaki Takahashi, Sarbajit Mukherjee

Zitieren

APA

Fujiwara, Y., Okamura, Y., Ramesh, M., Tehrani, Y. F., Aburaki, R., Takahashi, T., Ahluwalia, M. S., & Mukherjee, S. (2026). Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis. JNCI Cancer Spectrum, 10(4). https://doi.org/10.1093/jncics/pkag066

Vancouver

Fujiwara Y, Okamura Y, Ramesh M, Tehrani YF, Aburaki R, Takahashi T, et al. Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis. JNCI Cancer Spectrum. 2026;10(4). doi:10.1093/jncics/pkag066

BibTeX
@article{Fujiwara2026,
  author = {Fujiwara, Yu and Okamura, Yui and Ramesh, Mrinalini and Tehrani, Yasmin Fakhari and Aburaki, Riona and Takahashi, Toshiaki and Ahluwalia, Manmeet S and Mukherjee, Sarbajit},
  title = {Safety of immune checkpoint modulators beyond PD-1/PD-L1 and CTLA-4 in solid tumors: a meta-analysis},
  journal = {JNCI Cancer Spectrum},
  year = {2026},
  volume = {10},
  number = {4},
  doi = {10.1093/jncics/pkag066}
}
Kostenlos starten →